OQS
GTHX

Occudo Quantitative Strategies’s G1 Therapeutics, Inc. Common Stock GTHX Stock Holding History

Occudo Quantitative Strategies’s Portfolio GTHX Stock Details GTHX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q3 		– Sell
-112,793
Closed -$281K – 1378
2023
Q2 		$281K Buy
+112,793
New +$308K 0.03% 756
2022
Q4 		– Sell
-116,303
Closed -$1.45M – 1459
2022
Q3 		$1.45M Buy
+116,303
New +$1.33M 0.11% 269

Other funds holding GTHX

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
RJA
Raymond James & Associates St Petersburg, Florida $164B AUM 33.91% 1-Year Est. Return
Jacobs Levy Equity Management
Jacobs Levy Equity Management Florham Park, New Jersey $23.8B AUM 25.4% 1-Year Est. Return
Marshall Wace
Marshall Wace London, United Kingdom $100B AUM 35.1% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
XT
XTX Topco George Town, Cayman Islands $5.75B AUM 30.56% 1-Year Est. Return

Occudo Quantitative Strategies's GTHX Position: Q3 2023 in Review

Occudo Quantitative Strategies sold out of G1 Therapeutics, Inc. Common Stock (GTHX) in Q3 2023, closing a stake of 112,793 shares — an estimated $281K sold.

Occudo Quantitative Strategies first reported a position in GTHX in Q3 2022 and held it in 2 quarters. The position peaked at $1.45M in Q3 2022. 72 funds tracked by Wall St. Rank hold GTHX as of Q3 2023.

  • Occudo Quantitative Strategies reported no remaining G1 Therapeutics, Inc. Common Stock position as of Q3 2023 after selling out during the quarter.
  • Occudo Quantitative Strategies sold 112,793 G1 Therapeutics, Inc. Common Stock shares in Q3 2023, an estimated $281K.
  • Occudo Quantitative Strategies first reported a position in G1 Therapeutics, Inc. Common Stock in Q3 2022 and held it in 2 quarters.
  • Occudo Quantitative Strategies's G1 Therapeutics, Inc. Common Stock position peaked at $1.45M in Q3 2022.
  • 72 funds tracked by Wall St. Rank held G1 Therapeutics, Inc. Common Stock as of Q3 2023.

Based on Occudo Quantitative Strategies's 13F filing for Q3 2023, filed 14 Nov 2023.